骨髓增生肿瘤WHO2008修订分类及临床诊断方法

WHO revised diagnostic criteria for BCR-ABL-negative myeloproliferative disorders and diagnostic algorithms

新近对BCR-ABL阴性慢性骨髓增殖性疾病(CMPD)的分子发病机理研究取得重要进展,使该类疾病的分子诊断和遗传学分类成为可能。因此,WHO于2008年对该类疾病的诊断标准进行了相应修订,将分子发病机理的新信息加入相应类型疾病的诊断标准中。本文介绍这些诊断和分类方面的新变化及临床实践中相应类型的诊断方法。

Recent discoveries in the molecular pathogenesis of BCR -ABL -negative myeloproliferative disorders （MPDs） have raised the prospect of genetic classification and molecular diagnosis in these disorders. The WHO diagnostic criteria for the classic BCR -ABL- negative MPDs （that is PV, ET and PMF） have also been revised, in the 2008 edition, by incorporating new information on their molecular pathogenesis. The current review highlights these changes and also provides diagnostic algorithms that are tailored to routine clinical practice.